Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, prolonging active GLP-1 and GIP levels to increase insulin synthesis and decrease glucagon secretion. It is unique among DPP-4 inhibitors due to its primarily non-renal clearance.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety and efficacy:** Established for pediatric patients aged 10 years and older with T2DM.
* **Dose:** 5 mg orally once daily.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required in patients with renal impairment (creatinine clearance as low as 15 mL/min or ESRD).
* **Hepatic Impairment:** No dose adjustment required in patients with hepatic impairment.
## Contraindications
* Hypersensitivity to linagliptin (anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis (use clinical judgment).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with secretagogues or insulin).
* **Serious:** Acute pancreatitis, bullous pemphigoid, severe joint pain (arthralgia), hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** Decreases linagliptin plasma concentrations. If co-administration is necessary, monitor glycemic control closely as linagliptin efficacy may be reduced.
* **Sulfonylureas/Insulin:** Risk of hypoglycemia may increase; dose reduction of the secretagogue or insulin may be required.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months), fasting plasma glucose.
* **Clinical:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and hypersensitivity reactions. Monitor skin integrity for bullous pemphigoid.
## Clinical Pearls
* **Hepatic/Renal Advantage:** Unlike saxagliptin or sitagliptin, linagliptin does not require renal dose adjustments, making it a preferred choice for patients with chronic kidney disease (CKD).
* **Administration:** May be taken with or without food.
* **Weight/BP:** Weight neutral; has no clinically significant effect on blood pressure.
* **Uncertainty:** Long-term cardiovascular safety data are generally favorable but still evolve; monitor for symptoms of heart failure, although the association is less robust for linagliptin than for saxagliptin.
***
**Educational Disclaimer:** This information is for educational purposes and does not constitute medical advice. Please consult current prescribing information (FDA labels/package inserts) and institutional protocols before prescribing or administering medication.
